Concord Healthcare Group Co., Ltd. announced a leadership transition on 8 April 2026. Executive Director Fu Xiao, who has reached retirement age, has tendered her resignation and will serve as an advisor once a successor is confirmed. Her departure will become effective after shareholders elect a new executive director at the Annual General Meeting scheduled for 11 May 2026.

The Board has nominated President Jiang Wei, aged 45, to fill the vacancy. His appointment requires shareholder approval at the AGM and, if endorsed, will run through the remainder of the fourth Board session.

Jiang joined Concord Healthcare in 2020 and currently leads the Group’s oncology-focused AI business, Beijing Healthingkon Technology Co., Ltd. He also chairs Shanghai Concord Medical Diagnostic Imaging and holds directorships at Guangzhou Concord Cancer Center and Shanghai Concord Medical Cancer Hospital. Prior roles include chief financial officer of Concord Medical Services Holdings, four years at Ernst & Young (2003–2007) and thirteen years at China International Capital Corporation (2007–2020). Jiang holds a Bachelor of Finance and an MBA from Peking University.

According to the announcement, Jiang will concentrate on integrating the Group’s clinical and data resources with AI technologies, deepening its presence in oncology diagnostics and treatment, and driving overseas expansion.

Concord Healthcare will execute a service contract with Jiang upon approval; his director remuneration will follow the policy to be voted on at the AGM, with full details to appear in the 2025 annual report. A circular containing further information will be dispatched to shareholders in due course.

As of 8 April 2026, the Board comprises three executive directors, three non-executive directors and three independent non-executive directors.